Skip to main content

Table 1 Baseline clinical and biochemical characteristics of Chinese type 2 diabetic patients with no history of cardiovascular disease (CVD) divided according to the development of CVD during 4.9 (2.8-7.0) years of follow-up

From: Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study

 

Non-CVD (n = 4150)

CVD (n = 371)

 
 

median or%

IQR*

median or%

IQR*

P value

Age (years)

54

21

64

16

<.0001‡

Male Gender

45.7% (1898)

 

52.8% (196)

 

.0086

Smoking status

    

<.0001†

   Ex smoker

13.3% (553)

 

20.2% (75)

  

   Current smoker

14.9% (620)

 

21.2% (78)

  

Waist circumference (men, cm)

87.5

12.5

88.0

11.0

.2384

Waist circumference (women, cm)

82.5

13.0

84.5

13.0

.0165

Body mass index (kg/m2)

24.6

5.0

24.9

4.3

.4409

Duration of diabetes (Years)

5

9

9

10

<.0001‡

Systolic blood pressure (mmHg)

132

25

141

25

<.0001‡

Diastolic blood pressure (mmHg)

75

14

75

13

.1313‡

HbA1c (%)

7.2

2.1

7.7

2.6

<.0001‡

Spot urine albumin creatinine ratio (mg/mmol)

1.55

5.75

7.13

54.8

<.0001‡

eGFR (ml min-1 1.73 m-2) ξ

109

39

93

41

<.0001‡

LDL-C (mmol/L)

3.1

1.2

3.4

1.3

<.0001‡

   ≥3.0 mmol/L

56.1%(2330)

 

69.0%(256)

 

<.0001†

HDL-C (mmol/L)

1.28

0.45

1.18

0.45

<.0001‡

   HDL-C <1.0 in male or 1.3 in female

23.8%(987)

 

25.9%(96)

 

.3655†

Triglyceride (mmol/L)

1.27

0.97

1.40

1.01

.0031‡

Drug use at enrolment

     

Use of antihypertensive drugs at enrolment

29.7%(1231)

 

42.3%(157)

 

<.0001†

Drug use during follow-up

     

Use of statins during follow-up

22.7%(942)

 

22.6%(84)

 

.9799†

Use of fibrates during follow-up

6.41%(266)

 

4.58%(17)

 

.1639†

Use of other lipid lowering drugs during follow-up

0.29% (12)

 

0.27% (1)

 

.3832 ††

Use of RAS inhibitors during follow-up

48.9% (2029)

 

62.5% (232)

 

<.0001†

Use of gliclazide during follow-up

43.7% (1814)

 

37.2% (138)

 

.0152†

Use of rosiglitazone during follow-up

4.9% (204)

 

1.6% (6)

 

.0038†

Use of other oral antidiabetic drugs during follow-up

79.0% (3280)

 

80.3% (298)

 

.5587†

Use of insulin during follow-up

32.4%(1345)

 

45.0%(167)

 

<.0001†

Events during follow-up

     

Death during follow-up

5.42% (225)

 

27.5%(102)

 

<.0001†

  1. *, Median (IQR = interquartile range); †, derived from Chi-square test; ††, Derived from Fisher's exact test; ‡, derived from Wilcoxon two-sample test; ξ, eGFR = glomerular filtration rate from modified MDRD formula; ¶, including drug use at enrolment except for statins and fibrates (users at enrolment were excluded)